L. Nottebaum

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.

Parantu K. Shah, A. Protopopov, B. Vangamudi, 2015, Cancer research.

Identification of differential melanocortin 4 receptor agonist profiles at natively expressed receptors in rat cortical astrocytes and recombinantly expressed receptors in human embryonic kidney cells

L. Nottebaum, S. Lechner, J. Selkirk, 2007, Neuropharmacology.

Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects.

Gregory W. Kauffman, J. Edgerton, S. Steyn, 2016, Journal of medicinal chemistry.

Manipulation of small-molecule inhibitory kinetics modulates MCH-R1 function

R. Maki, Mingzhu Zhang, J. Grey, 2006, Molecular and Cellular Endocrinology.

A Novel Cell-Based Assay for G-Protein-Coupled Receptor-Mediated Cyclic Adenosine Monophosphate Response Element Binding Protein Phosphorylation

A. Foster, L. Nottebaum, S. Lechner, 2006, Journal of biomolecular screening.

Design and Synthesis of γ- and δ-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity.

C. Thorn, T. Kenakin, J. Edgerton, 2017, Journal of medicinal chemistry.

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.

Parantu K. Shah, A. Protopopov, B. Vangamudi, 2015, Cancer research.